Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Alx Oncology Holdings Inc Is A Clinical-Stage Immuno-Oncology Company Focused On Helping Patients Fight Cancer By Developing A Pipeline Of Product Candidates Based On Expertise In Protein Engineering And Oncology Led By The Cd47 Blocker, Evorpacept, Currently In Phase 1 And 2 Clinical Trials. Cancer Cells Leverage Cd47, A Cell Surface Protein, As A Don'T Eat Me Signal To Evade Detection By The Immune System. It Is Developing A Next-Generation Checkpoint Inhibitor Designed To Have A High Affinity For Cd47 And To Avoid The Limitations Caused By Hematologic Toxicities Inherent In Other Cd47 Blocking Approaches.